Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Abstract Background Real-world comparisons of biologic treatment outcomes for ulcerative colitis (UC) or Crohn’s disease (CD) patients are limited. We sought to evaluate the real-world effectiveness of vedolizumab (VDZ) and anti-tumor necrosis factor alpha (anti-TNFα) in UC and CD patients in German...

Full description

Bibliographic Details
Main Authors: Ulf Helwig, Michael Mross, Stefan Schubert, Heinz Hartmann, Alina Brandes, Dara Stein, Christian Kempf, Jana Knop, Sarah Campbell-Hill, Robert Ehehalt
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Gastroenterology
Subjects:
Inflammatory bowel disease
Crohn’s disease
Ulcerative colitis
Outcomes research
Vedolizumab
Real-world evidence
Online Access:http://link.springer.com/article/10.1186/s12876-020-01332-w

Internet

http://link.springer.com/article/10.1186/s12876-020-01332-w

Similar Items